Regulatory and methodologic challenges to tocolytic development

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 113, Issue SUPPL. 3, 2006, Pages 100-104

  Goodwin, T M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Approval; Placebo controlled trial; Surrogate markers; Tocolytic drug development

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATOSIBAN; GLYCERYL TRINITRATE; HEXOPRENALINE; ORPHAN DRUG; RITODRINE; UTERUS SPASMOLYTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DISEASE MARKER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GESTATIONAL AGE; HUMAN; PATHOPHYSIOLOGY; PERINATAL MORTALITY; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; TOCOLYSIS; TREATMENT OUTCOME; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FEMALE; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; TOCOLYTIC AGENTS;

EID: 33845569111     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2006.01133.x     Document Type: Review

References (11)

1. Tufts Center for the Study of Drug Development Backgrounder: How New Drugs Move Through the Development and Approval Process. Boston, 2001. [http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=4]. Accessed 18 October 2006.
2. Innovation - Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. US Department of Health and Human Services, Food and Drug Administration, 2004. [http://csdd.tufts.edu/NewsEvents/RecentNews.asp? newsid=4]. Accessed 18 October 2006.
3. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000;182:1173-83.
4. Ancel P, Livinec F, Larroque B, Marret S, Arnaud C, Pierrat V, et al. Cerebral palsy among very preterm children in relation to gestational age and neonatal ultrasound abnormalities: the EPIPAGE Cohort Study. Pediatrics 2006;117:828-35.
5. Lieman JM, Brumfield CG, Carlo W, Ramsey PS. Preterm premature rupture of membranes: is there an optimal gestational age for delivery? Obstet Gynecol 2005;105:12-17.
6. Tsoi E, Akmal S, Geerts L, Jeffery B, Nicolaides KH. Sonographic measurement of cervical length and fetal fibronectin testing in threatened preterm labor. Ultrasound Obstet Gynecol 2006;27:368-72.
7. The Canadian Preterm Labor Investigators Group. Treatment of preterm labor with the beta adrenergic agonist ritodrine. N Engl J Med 1992;327:308-12.
8. Goodwin TM, Randall H, Perry K, Menard MK, Bauer C, Shangold G, et al. A report on infant outcomes at 6 and 12 months after the use of atosiban in the management of preterm labor. American College of Obstetricians and Gynecologists, New Orleans, LA, USA, May 1998.
9. Houtzager BA, Hogendoorn SM, Papatsonis DN, Samsom JF, van Geijn HP, Bleker OP, et al. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG 2006;113:324-31.
10. Smith GN, Walker MC, Ohlsson A, et al. The use of transdermal nitroglycerin for preterm labor. Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada, March 22-25, 2006.
11. Milne CP. The Food and Drug Modernization Act and the Food and Drug Administration: metamorphosis or makeover? Drug Information Journal 2000;34:681-92.